CORELAB SOFTWARE

Street Address Here
Singapore, 2222

urwebsitename.com
urname@email.com

+000 12345 6789
+000 12345 6789

Mr. John Doe
Age / Sex : 44 Years / Male
Reg. No : 93

Registered on : 23/05/2026 4:18 PM
Referred By : Dr. Jack

Lipid Profile

BIOCHEMISTRY

TEST	VALUE	UNIT	REFERENCE
Total Cholesterol	162.5	mg/dl	125 - 200
HDL Cholesterol	57.5	mg/dl	35 - 80
Triglycerides	112.5	mg/dl	25 - 200
VLDL Cholesterol	*22.5*	*mg/dL*	*< 30*
LDL Cholesterol	*82.5*	*mg/dL*	*< 100*
Non-HDL Cholesterol	*105*	*mg/dL*	*< 130*
Total Cholesterol / HDL Ratio	*2.83*	*ratio*	*< 5*
LDL/HDL Ratio	*1.43*	*ratio*	*< 3.5*

Interpretations:

Abnormalities of lipids are associated with increased risk of coronary artery disease (CAD) in patients with DM. This risk can be reduced by intensive treatment of lipid abnormalities. The usual pattern of lipid abnormalities in type 2 DM is elevated triglycerides, decreased HDL cholesterol and higher proportion of small, dense LDL particles. Cholesterol is a lipid found in all cell membranes and in blood plasma. It is an essential component of the cell membranes, and is necessary for synthesis of steroid hormones, and for the formation of bile acids. Cholesterol is synthesized by the liver and many other organs, and is also ingested in the diet. Triglycerides are lipids in which three long-chain fatty acids are attached to glycerol. They are present in dietary fat and also synthesized by liver and adipose tissue.

Newer treatment goals and statin initiation thresholds based on the risk categories proposed by Lipid Association of India in 2020.

Risk Category	**Treatment Goal**		**Consider Therapy**	
	LDL Cholesterol (LDL-C) (Mg/dl)	**Non-HDL Cholesterol (Non HDL-C) (Mg/dl)**	**LDL cholesterol (LDL-C) (Mg/dl)**	**Non- HDL Cholesterol (Non HDL-C) (Mg/dl)**
Extreme Risk Group Category A	< 50 (Optional Goal<=30)	<80 (Optional Goal<=60)	>=50	>=80
Extreme Risk Group Category A	<=30	<=60	>30	>60
Very High	<50	<80	>=50	>=80
High	<70	<100	>=70	>=100
Moderate	<100	<130	>=100	>=130
Low	<100	<130	>=130*	>=160*

*In low risk patient, consider therapy after an initial non-pharmacological intervention for at least 3 months.

~~~ End of report ~~~

Upload Signature

Upload Signature

Mr. xxxx
DMLT, Lab Incharge

Dr. yyyyy
MBBS, MD Pathologist
~~~